leisure time -WSS

leisure time

author：hotspot 2025-08-23 08:56:24 - browse：64

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose a significant amount of weight in an early trial, sending its shares up in early trading.

The drug, a once-weekly injection known as CT-388, resulted in an average placebo-adjusted weight loss of 18.8% after 24 weeks, the company said. The study was a Phase 1 trial, though it was placebo-controlled.

The reaction to such an early result — Roche shares were up roughly 4% early Thursday — is a signal both of the stakes of the obesity medication race and the keen interest investors have in the field.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Congress: Eradicate hepatitis C and reduce the deficit

hotspot

focus

entertainment

WSS

Federal judge rules Oregon’s tough new gun law is constitutional

5 wounded, 2 critically, in Michigan shopping center shooting

Everything to know for the next Powerball drawing as jackpot hits $1 billion

Argenx drug significantly slows progression of nerve disorder

J&J expands global access to TB drug amid advocacy campaign

Snowpack in the West is melting rapidly. Where will all that extra water go?

leisure time

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

Cancer drug shortages should be causing more outrage

Typhoon Doksuri makes landfall in China after bringing deadly landslides to Philippines

Bright Health sells Medicare Advantage business to Molina

Mike Pence clashes with Tucker Carlson in Iowa

ChatGPT in medicine: STAT answers readers' burning questions

'Weather

Jerome Adams on the need for new antivirals for Covid

What AstraZeneca

Duchenne breakthrough therapy leaves behind pioneering families

Involuntary treatment for addiction doesn't work

hotspot

Does aspartame cause cancer? What new WHO guidance says

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

Grail faces three suits alleging harassment, retaliation

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

Europe sees delivery challenges ahead on Alzheimer's therapies

Can CDC director Mandy Cohen drive consensus in Washington?

explore

focus

entertainment

focus